Clinical Research Progress of the Non-Peptide Oral Somatostatin Receptor Ligand Paltusotine
10.12376/j.issn.2097-0501.2023.03.012
- VernacularTitle:新型非肽类口服生长抑素受体配体paltusotine的临床研究进展
- Author:
Yuke LIU
1
;
Huiwen TAN
2
Author Information
1. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.Center for Pituitary Adnomas and Related Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
neuro-endocrine malignancies;
acromegaly;
somatostatin receptor ligands;
pharmacokinetics;
pharmacodynamics
- From:
JOURNAL OF RARE DISEASES
2023;2(3):414-419
- CountryChina
- Language:Chinese
-
Abstract:
The research and development of somatostatin analogues is a hot area in endocrinology and metabolism. The first generation octreotide, lanreotide and the second generation pareotide have been approved to be effective for the treatment of neuroendocrine tumors such as acromegaly. However, paltusotine, a somatostatin receptor ligand, is a novel non-peptide small molecule drug which can be administered orally and inhibits excessive secretion of growth hormone and insulin-like growth factor 1. This review summarizes the research progress of the pharmacokinetics, pharmacodynamics, clinical efficacy, telerability, and safety of paltusotine.
